Myriad Genetics, Inc. (NASDAQ:MYGN) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.

Shares of Myriad Genetics, Inc. (NASDAQ MYGN) traded up 1.35% during midday trading on Tuesday, reaching $25.55. 1,863,830 shares of the company were exchanged. Myriad Genetics, Inc. has a 12-month low of $15.15 and a 12-month high of $31.49. The company has a 50 day moving average price of $24.97 and a 200-day moving average price of $20.53. The stock has a market capitalization of $1.74 billion, a P/E ratio of 54.59 and a beta of 0.31.

MYGN has been the subject of several recent analyst reports. Jefferies Group LLC restated a hold rating and issued a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. Deutsche Bank AG upped their price objective on Myriad Genetics from $15.00 to $20.00 and gave the stock a sell rating in a report on Monday, May 8th. BidaskClub raised Myriad Genetics from a sell rating to a hold rating in a report on Friday, June 9th. J P Morgan Chase & Co reaffirmed an underweight rating and set a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th. Finally, Cowen and Company reaffirmed a hold rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. Myriad Genetics currently has a consensus rating of Hold and a consensus price target of $21.77.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with's FREE daily email newsletter.